|
Last Updated: Nov 17th, 2006 - 22:35:04 |
Latest Research
:
Pharmacology
:
PPI
Immediate-release Omeprazole Significantly Reduces Nocturnal Acidity
Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced the publication of clinical trial results in the June 15, 2005 issue of Alimentary Pharmacology & Therapeutics, a peer-reviewed gastroenterology journal.
Jun 15, 2005, 00:15
Latest Research
:
Pharmacology
:
PPI
NDA Filed for Omeprazole Chewable Tablets
Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced that it has submitted a New Drug Application (NDA) for ZEGERID(R) (omeprazole) Chewable Tablets 40 mg and 20 mg to the U.S. Food and Drug Administration (FDA).
May 27, 2005, 17:46
Latest Research
:
Pharmacology
:
PPI
:
Esomeprazole
Esomeprazole can reduce upper GI symptoms in patients using NSAIDS
Results from two clinical trials, published in the American Journal of Gastroenterology, demonstrate that NEXIUM� (esomeprazole magnesium) can reduce upper gastrointestinal (GI) symptoms � such as moderate to severe pain, burning and discomfort in the upper abdomen� associated with continuous, daily use of non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors.
May 13, 2005, 17:04
|
